Clinical Research

Clinical Trials

Sanofi MOVES-PD: Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson’s Disease Carrying a GBA Mutation or Other Pre-specified Variant

Sanofi US Services, Inc. is conducting a clinical trial in Parkinson’s Disease (PD) patients carrying a glucocerebrosidase (GBA) gene mutation (GBA-PD).

You may be eligible to participate in this study if you meet several criteria including the following:

  • Diagnosis of PD and are a known heterozygous carrier of a GBA mutation associated with PD
  • Age 18 to 80 years
  • Have symptoms of PD for at least 2 years
  • If you do not already know your GBA status, you can speak with the site personnel to find out how to get tested for the GBA gene.

Status: Recruiting

Learn more at clinicaltrials.gov. If you are interested, please call (650) 770-0205 or email trials@thepi.org.

Center of Excellence

The Parkinson’s Institute and Clinical Center is designated as one of 45 worldwide Centers of Excellence for Parkinson’s treatment and research. This is a distinction awarded by the Parkinson’s Foundation.

Questions about making a donation? Please call (650) 770-0201.

Email News and Updates

Join our mailing list to receive the latest news and updates from our team.

Parkinson's Institute and Clinical Center
2500 Hospital Drive, Building 10, Suite 1 | Mountain View, CA 94040
(650) 770-0201 main | (650) 770-0204 fax (secure clinic fax)

Federal Tax ID # 94-3061594